Glp – 3 (RT) – 10MG
About Glp – 3 (RT) – 10MG
Retatrutide (development code LY3437943), marketed by the client as "GLP-3," is a synthetic single-molecule peptide of 39 amino acids engineered as a first-in-class triple incretin receptor agonist. In experimental characterization it activates three class B G-protein-coupled receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Its backbone incorporates aminoisobutyric acid (Aib) substitutions and fatty-acid acylation designed to confer protease resistance and extended circulating half-life.
In preclinical and in-vitro research, retatrutide has been used to study the pharmacology of combined incretin and glucagon-receptor engagement, including effects on energy metabolism, glucose handling, and adiposity in animal models. Its balanced triple-agonist profile distinguishes it from single (GLP-1R) and dual (GIP/GLP-1) agonists and has made it a subject of intense metabolic-research interest. This material is supplied strictly for Research Use Only.
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
Handling and Storage Tips:
Keep peptides cold and away from light once received.
For short-term use (days to weeks), refrigeration at 4°C (39°F) is acceptable.
Lyophilized peptides are typically stable at room temperature for several weeks, making it suitable for moderate-term storage.
For long-term storage (months to years), it’s best to freeze peptides at -80°C (-112°F). Freezing optimally preserves peptide stability for extended periods.
FDA Disclosure & Intended Use:
FDA Disclosure: The statements on this website and the products sold herein have not been evaluated by the U.S. Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. Products sold are for Research Use Only and are not for human or animal use.
Intended Purpose: Products sold on this site are intended solely for basic laboratory research, pharmaceutical research, or the development of new tests. They are not intended for diagnostic, therapeutic, or clinical use.
Specifications
- MaterialGlp – 3 (RT) – 10MG
- Also searched asGLP3, GLP 3, Retatrutide, LY3437943
- Research AreaMetabolic Research
- Presentation—
- CAS Number2381089-83-2
- Molecular FormulaC221H342N46O68
- Molecular Weight4731.34 g/mol
- TypeSynthetic acylated peptide (triple incretin agonist)
- Receptor / TargetGIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR)
- PubChem CID171934787 →
Y-Aib-QGTFTSDYSILLDKKAQ-Aib-AFIEYLLEGGPSSGAPPPS (39 residues, dual fatty-acid acylated)
- Purity (HPLC)≥99%
- Identity (MS)Confirmed to specification
- TestingAccredited (ISO 17025) third-party laboratory
- DocumentationPer-batch COA →
Published preclinical and early-phase research characterizes retatrutide as a balanced agonist across GIPR, GLP-1R, and GCGR, with in-vitro potency data reported for each receptor. In animal models it has been associated with changes in body weight, food intake, and glucose parameters attributed to its combined incretin and glucagon-receptor activity.
These observations derive from experimental, preclinical, and early clinical-pharmacology settings and are provided for scientific context only. No human efficacy, dosing, or therapeutic conclusions are implied by this listing.
Retatrutide (LY3437943) was developed by Eli Lilly as a triple GIP/GLP-1/glucagon receptor agonist, building on the incretin biology established by earlier GLP-1 and dual GIP/GLP-1 agonists. Coskun and colleagues published its discovery and pharmacology, and it subsequently advanced through clinical evaluation as an investigational metabolic agent.
- Coskun T, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism.
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine.
- Rosenstock J, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial. The Lancet.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. This material is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
Are these research materials third-party tested?
Yes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.
What purity are the materials?
Materials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.
Do you provide a Certificate of Analysis (COA)?
Yes. Per-batch COA documentation is provided and is traceable by lot number.
Where do you ship from?
Materials are shipped from the USA in discreet, protective packaging.
Are these products for human use?
No. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.
More Metabolic Research materials
✓ ≥99% View COA ›
MOTS-c 10MG Research Vial - Mitochondrial-Derived Peptide | Third-Party Tested
✓ ≥99% View COA ›
GLP-3 (Retatrutide) 15MG Research Vial - GLP-1/GIP/Glucagon Triple Receptor Agonist | Third-Party Tested
RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE · 21+
